金達威(002626.SZ):取得"一種利用微生物發酵生產DHA的方法"發明專利證書
格隆匯 8 月 26日丨金達威(002626.SZ)公告,公司及全資子公司內蒙古金達威藥業有限公司近日收到國家知識產權局頒發的發明專利證書,具體情況如下:
發明名稱:一種利用微生物發酵生產DHA的方法
專利號:ZL201611270522.9
專利申請日:2016年12月30日
專利權人:內蒙古金達威藥業有限公司
廈門金達威集團股份有限公司
專利權期限:二十年
證書號:第3918545號
授權公告日:2020年08月04日
本發明涉及一種利用微生物發酵生產DHA的方法,本發明的方法制備DHA,產量高,純度高,並且有利於DHA的大規模工業化生產。
上述專利的取得不會對公司生產經營產生重大影響,但有利於公司的技術創新,充分發揮自主知識產權優勢,進一步完善知識產權保護體系,增強公司的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.